AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 9597244
Drug: Four-drug regimen
RxNorm normalized name: Four-Way
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Four-drug regimen (standard treatment)
Trial: 9597244
Drug: Five-drug regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Five-drug regimen (four drugs plus levofloxacin)
Trial: 9597244
Drug: 9 months
RxNorm normalized name: treprostinil
DrugBank: Treprostinil (DB00374)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 9 months of intermittent therapy with isoniazid and rifampin
Trial: 9597244
Drug: 6 months
RxNorm normalized name: leuprolide 45 mg/6 months intramuscular kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 months of intermittent therapy with isoniazid and rifampin
Trial: 3108009
Drug: Transdermal nitroglycerin
RxNorm normalized name: nitroglycerin Transdermal System
DrugBank: Nitroglycerin (DB00727)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal nitroglycerin (Nitroderm‐TTS)
Trial: 29440149
Drug: Multimodal cachexia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multimodal cachexia intervention (MENAC trial) including non-steroidal anti-inflammatory drugs, eicosapentaenoic acid, physical exercise program (resistance and aerobic training), dietary counselling, and oral nutritional supplements.
Trial: 26170027
Drug: RTA 408
RxNorm normalized name: RTA 744
DrugBank: RTA 744 (DB05920)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RTA 408 Lotion (0.5%, 1%, and 3%) applied twice daily for 14 days
Trial: 26170027
Drug: RTA 408
RxNorm normalized name: RTA 744
DrugBank: RTA 744 (DB05920)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RTA 408 Lotion (3%) applied twice daily to a 100-cm² site for 14 days
Trial: 26170027
Drug: RTA 408
RxNorm normalized name: RTA 744
DrugBank: RTA 744 (DB05920)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RTA 408 Lotion (3%) applied twice daily to a 500-cm² site for 28 days
Trial: 26170027
Drug: Lotion vehicle
RxNorm normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lotion vehicle applied as control
Trial: 23682979
Drug: Immediate antibiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate antibiotic treatment
Trial: 23682979
Drug: Delayed antibiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed antibiotic prescribing (DAP) with structured advice to use a course of antibiotics if symptoms worsen or do not improve (prescription given to patient)
Trial: 23682979
Drug: Delayed antibiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed antibiotic prescribing (DAP) with structured advice to use a course of antibiotics if symptoms worsen or do not improve (prescription left at the reception of the primary care centre 3 days after the first medical visit)
Trial: 21845445
Drug: FRG-E (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FRG-E (500 μg mouse(‐1))
Trial: 12733686
Drug: Lowering intraocular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lowering intraocular pressure (IOP) through various treatments, specific interventions not detailed, duration not specified.
Trial: 1733754
Drug: Valproate therapy
RxNorm normalized name: valproate
DrugBank: Valproic acid (DB00313)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Valproate therapy (VPA)
Trial: 29996802
Drug: Lyophilised vaccines
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lyophilised vaccines (BCG, Measles, Yellow Fever)
Trial: 29996802
Drug: Multi-dose/single dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multi-dose/single dose vials of liquid vaccines
Trial: 27514506
Drug: Azilsartan medoxomil
RxNorm normalized name: Azilsartan Medoxomil
DrugBank: Azilsartan medoxomil (DB08822)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Azilsartan medoxomil (80 mg) and chlorthalidone (25 mg) in fasted condition
Trial: 27514506
Drug: Azilsartan medoxomil
RxNorm normalized name: Azilsartan Medoxomil
DrugBank: Azilsartan medoxomil (DB08822)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Azilsartan medoxomil (80 mg) and chlorthalidone (25 mg) 30 minutes after a high‐fat meal
Trial: 27514506
Drug: Fixed-dose combination
RxNorm normalized name: Progestogens and estrogens, fixed combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed-dose combination (FDC) of azilsartan medoxomil and chlorthalidone in fasted condition
Trial: 27514506
Drug: Fixed-dose combination
RxNorm normalized name: Progestogens and estrogens, fixed combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed-dose combination (FDC) of azilsartan medoxomil and chlorthalidone 30 minutes after a high‐fat meal
Trial: 24747488
Drug: Home-based Behavioral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Home-based Behavioral Activation for Depression (BATD) treatment delivered via web-based video technology
Trial: 24747488
Drug: In-office Behavioral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In-office Behavioral Activation for Depression (BATD) treatment
Trial: 23285070
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg L-dopa (Madopar)
Trial: 20469975
Drug: Amlodipine/valsartan 5/80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amlodipine/valsartan 5/80 mg
Trial: 20469975
Drug: Amlodipine/valsartan 5/80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amlodipine/valsartan 5/80 mg (subgroup n = 82)
Trial: 10221486
Drug: Thymoglobulin (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thymoglobulin (1.5 mg/kg intravenously)
Trial: 10221486
Drug: Atgam (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atgam (15 mg/kg intravenously)
Trial: 8590509
Drug: 13.5 mg
RxNorm normalized name: niacin 13.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 13.5 mg hyperbaric bupivacaine 0.75% + 25 micrograms fentanyl intrathecal (Group II)
Trial: 8590509
Drug: 13.5 mg
RxNorm normalized name: niacin 13.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 13.5 mg hyperbaric bupivacaine 0.75% + 0.5 ml CSF (Group I)
Trial: 108663
Drug: 10% dextrose-amino
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10% dextrose-amino acid solution
Trial: 108663
Drug: 10% dextrose-amino
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10% dextrose-amino acid with intravenous fat emulsion
Trial: 21623968
Drug: Inhaled corticosteroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled corticosteroids (ICS) - 200 μg beclomethasone extra-fine daily for 8 weeks
Trial: 19218828
Drug: Single-family therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-family therapy (n = 25)
Trial: 19218828
Drug: Multi-family group
RxNorm normalized name: Parasedge Multi
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multi-family group therapy (n = 35)
Trial: 19218828
Drug: Treatment as
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment as usual (n = 23)
Trial: 11672450
Drug: Lisinopril (5-20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lisinopril (5-20 mg daily)
Trial: 9338727
Drug: Bacille Calmette-Guérin
RxNorm normalized name: BACILLUS CALMETTE-GUERIN,TICE VACCINE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bacille Calmette-Guérin (BCG) 150 mg
Trial: 11552904
Drug: Omeprazole 20
RxNorm normalized name: omeprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 20 mg o.m.
Trial: 3322922
Drug: Cimetidine 400
RxNorm normalized name: cimetidine 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine 400 mg b.i.d.
Trial: 23507375
Drug: Allopurinol (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Allopurinol (300 mg orally, administered 4 hours before a match)
Trial: 23507375
Drug: Placebo (cellulose,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (cellulose, administered 4 hours before a match)
Trial: 20008243
Drug: Induction therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction therapy with lenalidomide, bortezomib, and dexamethasone
Trial: 20008243
Drug: High-dose chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose chemotherapy with a single autologous stem cell transplant
Trial: 15108985
Drug: Intrathecal hyperbaric
RxNorm normalized name: beractant
DrugBank: Beractant (DB06761)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intrathecal hyperbaric bupivacaine (6, 7, 8, 9, 10, 11, or 12 mg) with 10 microg intrathecal fentanyl and 200 microg intrathecal morphine
Trial: 11268890
Drug: Long-term oxygen
RxNorm normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Long-term oxygen therapy (LTO)
Trial: 11268890
Drug: Surgical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical therapy (bilateral reduction of lung volume)
Trial: 11268890
Drug: Nutritional therapy
RxNorm normalized name: nutritional therapy for GSD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nutritional therapy (special diets)
Trial: 11268890
Drug: Psycho-social interventions
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Psycho-social interventions (e.g. psychotherapy, training and education)
Trial: 9847435
Drug: Racemic albuterol
RxNorm normalized name: Albuterol
DrugBank: Albuterol (DB01001)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Racemic albuterol 1.25 mg
Trial: 25692656
Drug: Freeze dried
RxNorm normalized name: BLACKBERRY MESOCARP FREEZE DRIED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Freeze dried live attenuated Oka strain Varicella Vaccine (VR 795 Oka strain)
Trial: 25692656
Drug: Freeze dried
RxNorm normalized name: BLACKBERRY MESOCARP FREEZE DRIED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Freeze dried live attenuated Oka strain Varicella Vaccine (VR 795 Oka strain) and Varilrix (Oka-RIT strain)
Trial: 18509557
Drug: Manual therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manual therapy (anterior‐posterior joint mobilization over the talus) plus standard physiotherapy programme
Trial: 18509557
Drug: Manual therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manual therapy plus standard physiotherapy programme
Trial: 7751524
Drug: Topical treatment
RxNorm normalized name: Hongo Killer Treatment Topical Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical treatment with atropine
Trial: 2717665
Drug: 5-HT agonist
RxNorm normalized name: 5-HT
DrugBank: Serotonin (DB08839)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-HT agonist (fluoxetine)
Trial: 2717665
Drug: 5-HT antagonist
RxNorm normalized name: 5-HT
DrugBank: Serotonin (DB08839)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-HT antagonist (ritanserin)
Trial: 142468
Drug: Isosorbide (osmotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isosorbide (osmotic anti-glaucoma medication)
Trial: 31438412
Drug: Mobile application
RxNorm normalized name: Mahana IBS CBT Mobile Application
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mobile application for medication management
Trial: 22577108
Drug: Cinacalcet (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cinacalcet (30 mg daily, titrated until calcium normalization)
Trial: 19307987
Drug: Medication-only condition
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication-only condition
Trial: 19485586
Drug: Combined medication
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined medication plus cognitive-behavioral therapy (CBT) condition
Trial: 17543129
Drug: Nebulized albuterol
RxNorm normalized name: Albuterol
DrugBank: Albuterol (DB01001)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebulized albuterol (2.5 mgr)
Trial: 9821232
Drug: Ramipril 2.5‐10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ramipril 2.5‐10 mg/day
Trial: 7965279
Drug: Captopril 100
RxNorm normalized name: captopril 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril 100 mg twice a day
Trial: 8121291
Drug: Mepacrine hydrochloride
RxNorm normalized name: Mepacrine hydrochloride
DrugBank: Quinacrine (DB01103)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mepacrine hydrochloride 100 mg three times daily for 7 days
Trial: 23383047
Drug: antibiotic use
RxNorm normalized name: Antibiotics for systemic use
FDA approved: no
EMA approved: no
PMDA approved: no
Description: antibiotic use
Trial: 20574663
Drug: Palonosetron (0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Palonosetron (0.25 mg intravenously) and dexamethasone (8 mg intravenously) on day 1
Trial: 20574663
Drug: Palonosetron (0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Palonosetron (0.25 mg intravenously) and dexamethasone (8 mg intravenously) on day 1 followed by dexamethasone 8 mg orally on days 2 and 3
Trial: 19522441
Drug: New antiepileptic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New antiepileptic drugs (AED) with accurate pathogenic targets
Trial: 17140540
Drug: Dental treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dental treatment (full mouth rehabilitation under general anaesthesia)
Trial: 10705631
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg of octreotide‐acetate subcutaneously one hour prior to ERCP
Trial: 10705631
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg of octreotide‐acetate
Trial: 7560226
Drug: Systemic Augmentin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic Augmentin therapy (500 mg 1 h prior to surgery, 500 mg TID for 8 days)
Trial: 7560226
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no systemic antimicrobial therapy)
Trial: 1697419
Drug: Fluvoxamine (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluvoxamine (150 mg)
Trial: 1697419
Drug: Ritanserin (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ritanserin (20 mg)
Trial: 30999929
Drug: Namilumab 20
RxNorm normalized name: Namilumab
DrugBank: Namilumab (DB13037)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Namilumab 20 mg
Trial: 30999929
Drug: Namilumab (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Namilumab (all doses)
Trial: 24794075
Drug: Baseline PSA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baseline PSA <1.0 ng/ml
Trial: 24794075
Drug: Baseline PSA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baseline PSA 1-1.9 ng/ml
Trial: 24794075
Drug: Baseline PSA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baseline PSA 2-2.9 ng/ml
Trial: 24794075
Drug: Baseline PSA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baseline PSA 1-1.99 ng/ml
Trial: 24794075
Drug: Baseline PSA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baseline PSA 2-2.99 ng/ml
Trial: 22718472
Drug: Low-level laser
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-level laser therapy (LLLT), 10 sessions, 830 nm, output power of 50 mW, fluence of 707 J/cm² (L group, n=23)
Trial: 22718472
Drug: Placebo treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatment (P group, n=20)
Trial: 8988795
Drug: dextroamphetamine (0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: dextroamphetamine (0.25 mg/kg p.o.) + scopolamine (0.5 mg i.v.)
Trial: 19211454
Drug: 24 additional
RxNorm normalized name: chromous chloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 24 additional months of androgen deprivation therapy
Trial: 19211454
Drug: No additional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No additional therapy (control arm)
Trial: 16394038
Drug: Oxytocin (2.99
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxytocin (2.99 IU rapid intravenous infusion)
Trial: 16394038
Drug: Oxytocin (maximum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxytocin (maximum infusion dose 10.3 +/‐ 8.2 mU/min)
Trial: 19780299
Drug: Intraperitoneal (IP)
RxNorm normalized name: Intraperitoneal Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraperitoneal (IP) chemotherapy regimens
Trial: 19780299
Drug: Maintenance therapy
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maintenance therapy with IP cisplatin
Trial: 19780299
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy with intravenous cisplatin plus paclitaxel
Trial: 11475726
Drug: Radio- and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radio- and chemotherapy alone
Trial: 780061
Drug: salbutamol 8
RxNorm normalized name: Salbutamol
DrugBank: Albuterol (DB01001)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: salbutamol 8 mg tablets (2 tablets b.d.)
Trial: 780061
Drug: aminophylline 225
RxNorm normalized name: aminophylline 225 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: aminophylline 225 mg tablets (1 tablet b.d. increasing to 2 tablets b.d. after 1 week)
Trial: 20112492
Drug: Xiao yan
RxNorm normalized name: Xiao mai
DrugBank: Wheat (DB10579)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xiao yan li dan Pian (bile‐draining anti‐inflammatory tablet)
Trial: 8629630
Drug: mupirocin calcium
RxNorm normalized name: Mupirocin Calcium
DrugBank: Mupirocin (DB00410)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: mupirocin calcium ointment 2% applied daily to the exit site
Trial: 8629630
Drug: cyclic oral
RxNorm normalized name: cyclic AMP
DrugBank: Cyclic adenosine monophosphate (DB02527)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cyclic oral rifampin 600 mg for 5 days every 3 months
Trial: 6691784
Drug: Cognitive therapy
RxNorm normalized name: cognitive therapy software
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive therapy (N = 14)
Trial: 6691784
Drug: Pharmacotherapy (N
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacotherapy (N = 14)
Trial: 6691784
Drug: Cognitive therapy
RxNorm normalized name: cognitive therapy software
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive therapy and Pharmacotherapy (N = 28)
Trial: 31064968
Drug: Oral cryotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral cryotherapy during chemotherapy
Trial: 28620848
Drug: Standard-of-Care (SoC)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-of-Care (SoC) platinum-based chemotherapy
Trial: 23798725
Drug: telcagepant 600
RxNorm normalized name: Telcagepant
DrugBank: Telcagepant (DB12228)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: telcagepant 600 mg
Trial: 23798725
Drug: telcagepant 600
RxNorm normalized name: Telcagepant
DrugBank: Telcagepant (DB12228)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: telcagepant 600 mg with sumatriptan 100 mg
Trial: 19208459
Drug: Combined therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined therapy (arformoterol 15microg BID and tiotropium 18microg QD)
Trial: 11131273
Drug: Lisinopril 10-20
RxNorm normalized name: lisinopril 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lisinopril 10-20 mg daily for 8 weeks
Trial: 11131273
Drug: Nitrendipine 5-10
RxNorm normalized name: nitrendipine
DrugBank: Nitrendipine (DB01054)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitrendipine 5-10 mg daily for 8 weeks
Trial: 11131273
Drug: Nitrendipine 5-10
RxNorm normalized name: nitrendipine
DrugBank: Nitrendipine (DB01054)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitrendipine 5-10 mg daily for 8 weeks followed by Lisinopril 10-20 mg daily for another 8 weeks
Trial: 1606777
Drug: rHuEpo 40
RxNorm normalized name: GlycoPEGylated™rHuEPO
DrugBank: NE-180 (DB05619)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rHuEpo 40 U/kg intravenously three times weekly (Group 1)
Trial: 1606777
Drug: rHuEpo 40
RxNorm normalized name: GlycoPEGylated™rHuEPO
DrugBank: NE-180 (DB05619)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rHuEpo 40 U/kg intravenously three times weekly with nandrolone decanoate 2 mg/kg weekly (Group 2)
Trial: 2832549
Drug: Cisplatin 20
RxNorm normalized name: CISPLATIN 200MG/VIL (PF) INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisplatin 20 mg/m2 X 4 plus etoposide (VP‐16) 100 mg/m2 X 4 every 4 weeks for two courses
Trial: 28597226
Drug: AL 441
RxNorm normalized name: Al
DrugBank: Aluminium (DB01370)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AL 441 mg q4wk
Trial: 28597226
Drug: AL 882
RxNorm normalized name: Al
DrugBank: Aluminium (DB01370)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AL 882 mg q6wk
Trial: 28597226
Drug: AL 1064
RxNorm normalized name: Al
DrugBank: Aluminium (DB01370)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AL 1064 mg q8wk
Trial: 12687595
Drug: High-dose aerosol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose aerosol beclomethasone (2.40-3.69 microg/kg/day)
Trial: 12687595
Drug: Medium-dose aerosol
RxNorm normalized name: Medium-Chain Triglycerides
DrugBank: Medium-chain triglycerides (DB13959)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medium-dose aerosol beclomethasone (1.0-1.85 microg/kg/day)
Trial: 12687595
Drug: Low-dose aerosol
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose aerosol beclomethasone (0.48-0.74 microg/kg/day)
Trial: 8642081
Drug: 25% glycolic,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25% glycolic, lactic, or citric acid lotion